Physician profile
Jill E Groves
NPI 1700979119
$2,184.20
in general payments reported to CMS, 2019-2025
24 companies · $84.99 in 2025
The $84.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $382 · 2020: $369 · 2021: $624 · 2022: $388 · 2023: $202 · 2024: $133 · 2025: $84.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $357.29 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $324.88 | 2020-2023 | |
| Glaxosmithkline, LLC. | $315.88 | 2019-2023 | Shingrix, Bexsero, Pediarix |
| Intra-Sana Laboratories | $203.72 | 2024-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Sanofi-Aventis U.S. LLC | $156.82 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $135.76 | 2019-2021 | |
| Pfizer INC. | $131.49 | 2019-2021 | |
| Gilead Sciences, INC. | $96.34 | 2019-2020 | |
| Lilly USA, LLC | $79.62 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $59.94 | 2022-2023 | |
| Dexcom, INC. | $48.74 | 2021-2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $34.58 | 2019 | |
| Astellas Pharma US INC | $31.59 | 2022-2023 | Myrbetriq |
| E.R. Squibb & Sons, L.L.C. | $31.19 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $29.65 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $21.06 | 2023 | Kristalose |
| Janssen Pharmaceuticals, INC | $19.90 | 2021 | |
| Abbott Laboratories | $16.86 | 2023 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $16.29 | 2021 | |
| Hologic Sales and Service, LLC | $16.03 | 2019 | |
| Amgen INC. | $15.00 | 2020 | |
| Daiichi Sankyo INC. | $14.20 | 2020 | |
| Genentech USA, INC. | $14.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Groves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.